

AMENDMENTS

In the Specification:

Please replace paragraph [0108] with the following amended paragraph:

[0108] At the bottom of the Reaction Count and % of Reactions columns are numbers showing the number of incidents of the reactions at the Top 10 HLTs (488) ~~(12,950)~~ and the Total Reactions across all of the 256 HLTs (in this case, 1752 ~~62,669~~), 703 and 704, respectively.

Please replace paragraph [0113] with the following amended paragraph:

[0113] In this figure, the Concomitant Drugs Table 800 lists the top 10 drugs in the concomitant category. In this example, hydrochlorothiazide, aspirin, and furosemide ~~Lamivudine, Didanosine and Indinavir Sulfate~~ were among the drugs found in combination with Candesartan Cilexetil ~~Stavudine~~ in the adverse reactions reported to the FDA.

Please replace paragraph [0114] with the following amended paragraph:

[0114] The table divides the cases of concomitant drugs into two groups: Suspect and Non-suspect (fields 801 and 802, respectively). When an adverse reaction report is filed, certain drugs in the case may be indicated as suspect. When considering concomitant drugs, these drugs will be either suspect or not in the cases relating to the queried drug (in this case, Candesartan Cilexetil ~~Stavudine~~). Thus, in this example there are four cases to consider, suspect and non-suspect for the queried drug, and suspect and non-suspect for the concomitant drug.

Please replace paragraph [0115] with the following amended paragraph:

[0115] In the example, Hydrochlorothiazide ~~Lamivudine~~ is the drug found to be most frequently interacting with Candesartan Cilexetil ~~Stavudine~~. The total number of incidents (~~45~~ ~~12617~~) is broken out into the Suspect and Non-Suspect categories, and the total is also displayed as a percentage of cases that mention this concomitant drug (it is assumed a drug is only mentioned once per case), in this case 10.79% ~~100~~ of the total number of cases involving Candesartan Cilexetil ~~Stavudine~~. The remaining Top 10 concomitant drugs are listed in order of descending frequency.

Please replace paragraph [0143] with the following amended paragraph:

[0143] The Correlation Details screen of Figure 14 provides the data for each of the cases included in that pair of correlated terms. For example, if the term pair in the Correlated Terms Screen was "Female" "~~under 16~~" and "Candesartan Cilexetil," this screen provides the pertinent information for all of the cases where those two terms were paired. In this example, there were 18 ~~6~~ cases where renal function analyses were correlated with Candesartan Cilexetil. For each case, preferably the following information is provided: the case ID (field 1401); the gender of the patient (field 1402); the Manufacturer's Control Code (field 1403); the FDA Report Receipt Date (field 1404); the patient's age (field 1405); the other drugs the patient was taking at the time of the incident(s) (field 1406); the patient's reaction(s) to the medications (field 1407); and the outcome (field 1408). By selecting these cases, the user can then profile the set of cases.

Please replace paragraph [0157] with the following amended paragraph:

[0157] The comparator or differencing engine screen in the preferred offering offers three sets of analyzed data: Pre/Post Market data, Other Post-Market Reaction, and Other Clinical Trial

Reaction. An ~~exemplary~~ exemplary comparator screen is provided in Figure 20. The Pre/Post Market data is preferably organized into a series of columns in a first table (field 2000), providing the information, including Reaction HLT (field 2001); Clinical Trial Reaction ~~count~~ (field 2002); Clinical Trial Percentage (field 2003), Clinical Trial Adjusted Percentage (field 2004); Post Market Reaction ~~count~~ (field 2005); Post Market Percentage (field 2006); Post Market Adjusted Percentage (field 2007); and Difference Ratio (field 2008). The adjusted percentages account for proportions of those reactions that are common in both pre- and post-market reporting. The second table (field 2009) lists Other Post-Market Reaction (field 2010) and each reaction's Post-Market Percentage (field 2011). This information represents data available in the integrated public database. The third table (field 2012) provides Other Clinical Trial Reaction (field 2013) and each reaction's Clinical Trial Percentage (field 2014). This information indicates whether this reaction was mentioned on the manufacturer's package insert.

Please replace paragraph [0159] with the following amended paragraph:

[0159] In viewing the results of the system and method of the present invention, when a box on a table or in a matrix or a hyperlink is selected, the case listing is generated. When a user clicks on any of the numbers, he/she is provided with a listing of each of the cases corresponding to that link. An exemplary Case List is provided in Figure 21. For each case, various information is provided, including case ID (field 2100), gender (field 2101), Manufacturer Control Code (field 2102), FDS Report Receipt Date (field 2103), Age (field 2104), Drugs (field 2105), Reactions (field 2106), Seriousness ~~outcomes~~ (field 2107) (Y/N or normal outcome (optional)). These columns can be sorted by clicking on their headings. If a user selects a summary view, a profile of the cases in the case list is then calculated and displayed. Additionally, if a user wishes

to learn the details of a specific case, he/she can click on the case ID number of any specific case on the correlation details screen.